Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   CELL JOURNAL (YAKHTEH)   WINTER 2011 , Volume 12 , Number SUPPLEMENT 1 (THE 1ST INTERNATIONAL STUDENT CONGRESS ON CELL AND MOLECULAR MEDICINE); Page(s) 63 To 63.
 
Paper: 

GENETICS IN MEDICINE: P-51: THE ASSOCIATION STUDY OF XRCC1 GENE SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER

 
 
Author(s):  KHALILI AVATI M.*, SAADAT I., OMIDVARI S., SAADAT M.
 
* SHIRAZ UNIVERSITY, SHIRAZ, IRAN
 
Abstract: 

Objective: Primary treatment in locally advanced breast cancer is chemotherapy. A different response to similarchemotherapy schemes is one of the problems in this type of treatment. Among factors responsible for this variability, genetic variation plays important roles. The aim of present cohort study was to investigate the effect of genetic polymorphisms in XRCC1 gene (399 and 194 codons) on response to chemotherapy-based treatment.
Materials and Methods: DNA was extracted from peripheral blood of 98 patients with locally advanced breast cancer. Genotypes were determined using a RFLP-PCR method for XRCC1 polymorphisms.
Also information about tumor size after each cycle of chemotherapy was gathered from patient’s dossier.
Results: No significant association was obtained between XRCC1 Arg399Gln (
c2= 0.225, p=0.894) and Arg194Trp (c2= 0.485, p=0.784) polymorphisms and response rate to treatment. Conclusion: According to this finding, polymorphisms in XRCC1 gene had no effect on response rate to chemotherapy in locally advanced breast cancer.

Therefor exclude a role for XRCC1 polymorphisms (399 and 194 codons) as a prognostic factor in locally advanced breast cancer.

 
Keyword(s): BREAST CANSER, CHEMOTHERAPY, RESPONSE, XRCC1
 
References: 
  • ندارد
 
  Yearly Visit 51
 
Latest on Blog
Enter SID Blog